Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin

被引：0
|
作者：
Lush, C. [1 ]
Zhang, B. [1 ]
Maggs, D. [1 ]
Darsow, T. [1 ]
Kolterman, O. [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2007年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1258
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [1] Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
    Wysham, Carol
    Lush, Cameron
    Zhang, Bei
    Maier, Holly
    Wilhelim, Ken
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 79 - 85
  • [2] Pramlintide or mealtime insulin added to basal insulin treatment in patients with type 2 diabetes
    Riddle, M.
    Pencek, R.
    Charenkavanich, S.
    Lutz, K.
    Porter, L.
    Wilhelm, K.
    [J]. DIABETOLOGIA, 2008, 51 : S407 - S408
  • [3] Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
    Riddle, Matthew
    Pencek, Richard
    Charenkavanich, Supoat
    Lutz, Karen
    Wilhelm, Ken
    Porter, Lisa
    [J]. DIABETES CARE, 2009, 32 (09) : 1577 - 1582
  • [4] Pramlintide improved glycemic control without increased risk of hypoglycemia in patients with type 2 diabetes using basal insulin
    Lutz, Karen
    Maier, Holly
    Zhang, Bei
    Frias, Juan
    [J]. DIABETES, 2007, 56 : A143 - A143
  • [5] Comparison of Mealtime Pramlintide, Insulin, or a Combination of Both, When Added to Basal Insulin Treatment in Patients with Type 2 Diabetes
    Karounos, Dennis
    Pencek, Rich
    Huang, Wenying
    Miller, Stephan
    Lutz, Karen
    Porter, Lisa
    [J]. DIABETES, 2009, 58 : A32 - A32
  • [6] Comparison of mealtime pramlintide, insulin, or a combination of both, when added to basal insulin treatment in patients with type 2 diabetes
    Karounos, D.
    Pencek, R.
    Huang, W.
    Miller, S.
    Lutz, K.
    Porter, L.
    [J]. DIABETOLOGIA, 2009, 52 : S358 - S358
  • [7] Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin
    Riddle, Matthew
    Frias, Juan
    Zhang, Bei
    Maier, Holly
    Brown, Carl
    Lutz, Karen
    Kolterman, Orville
    [J]. DIABETES CARE, 2007, 30 (11) : 2794 - 2799
  • [8] Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
    Pullman, John
    Darsow, Tamara
    Frias, Juan P.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (03) : 203 - 212
  • [9] IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV
    Vilsboll, T.
    Blevins, T.
    Bode, B. W.
    Leiter, L. A.
    Poulter, N.
    Thurman, J.
    Agner, B. F. R.
    Lehmann, L.
    Jaeckel, E.
    [J]. DIABETOLOGIA, 2017, 60 : S52 - S52
  • [10] IDegLira Improves Cardiovascular Risk Markers in Patients with Type 2 Diabetes Uncontrolled on Basal Insulin: Analyses of DUAL II and DUAL V
    Vilsboll, Tina
    Blevins, Thomas C.
    Bode, Bruce
    Leiter, Lawrence A.
    Poulter, Neil
    Thurman, Jerry
    Agner, Bue F. Ross
    Lehmann, Lucine
    Jaeckel, Elmar
    [J]. DIABETES, 2017, 66 : A255 - A255
12345